```mermaid
flowchart TD
MAP1LC3["MAP1LC3<br/>LC3 Protein"]
ATG4B["ATG4B<br/>Protease"]
ATG_COMPLEX["ATG12-ATG5-ATG16L1<br/>Complex"]
ULK1["ULK1<br/>Kinase"]
BECN1["BECN1<br/>Beclin-1"]
SQSTM1["SQSTM1<br/>p62 Receptor"]
AUTOPHAGY["Autophagy<br/>Process"]
MITOPHAGY["Mitophagy<br/>Mitochondrial Cleanup"]
PARKIN["PARKIN<br/>E3 Ligase"]
RAPAMYCIN["Rapamycin<br/>mTOR Inhibitor"]
OXIDATIVE_STRESS["Oxidative Stress<br/>Response"]
NEURODEGENERATION["Neurodegeneration<br/>Outcome"]
AUTOPHAGY_BIOMARKER["LC3 Puncta<br/>Autophagy Biomarker"]
ULK1 -->|"initiates"| AUTOPHAGY
BECN1 -->|"regulates"| MAP1LC3
ATG4B -->|"processes"| MAP1LC3
ATG_COMPLEX -->|"conjugates"| MAP1LC3
MAP1LC3 -->|"activates"| AUTOPHAGY
MAP1LC3 -->|"binds"| SQSTM1
MAP1LC3 -->|"regulates"| ULK1
SQSTM1 -->|"targets cargo"| AUTOPHAGY
PARKIN -->|"upstream of"| MAP1LC3
MAP1LC3 -->|"enables"| MITOPHAGY
RAPAMYCIN -->|"activates"| MAP1LC3
MAP1LC3 -->|"participates in"| OXIDATIVE_STRESS
AUTOPHAGY -->|"prevents"| NEURODEGENERATION
MAP1LC3 -->|"forms"| AUTOPHAGY_BIOMARKER
Map1Lc3B2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@mizushima2011]
<table> [@nixon2013]
<tr><th colspan="2" style="background:#e8f4ea;">MAP1LC3B2 Protein</th></tr> [@jahreiss2008]
<tr><td><b>Protein Name</b></td><td>LC3B2 (Microtubule-Associated Protein 1 Light Chain 3 Beta 2)</td></tr> [@kuma2004]
<tr><td><b>Gene</b></td><td>[MAP1LC3B2](/genes/map1lc3b2)</td></tr>
<tr><td><b>UniProt ID</b></td><td>Q9GQL5</td></tr>
<tr><td><b>PDB ID</b></td><td>2K6R, 2L7Q</td></tr>
<tr><td><b>Molecular Weight</b></td><td>14.9 kDa (16.5 kDa lipidated)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm, Autophagosome, Lysosome</td></tr>
<tr><td><b>Protein Family</b></td><td>ATG8 family, MAP1 LC3 family</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>12p12.1</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke</td></tr>
</table>
</div>
MAP1LC3B2 (LC3B2) is a paralog of the well-characterized LC3B (MAP1LC3B) involved in autophagosome formation and selective autophagy. As a member of the ATG8 family, LC3B2 plays critical roles in neuronal autophagy, protein aggregate clearance, and cellular homeostasis in the brain.
LC3B2 is expressed primarily in testis and at lower levels in brain tissue, where it participates in the autophagy-lysosomal pathway. The protein undergoes post-translational lipidation (phosphatidylethanolamine conjugation) similar to other ATG8 family members, enabling its incorporation into autophagosomal membranes.
| Domain | Position | Function |
|--------|----------|----------|
| Ubiquitin-like fold | 1-120 | Core ATG8 structure |
| N-terminal region | 1-28 | Membrane interaction |
| LIR (LC3-Interacting Region) docking site | 13-16 | [Autophagy](/entities/autophagy) receptor binding |
| Phosphatidylethanolamine binding | 114-120 | Membrane anchoring |
| GABARAP interaction region | Various | Protein-protein interactions |
LC3B2 expression in the brain:
LC3B2 participates in:
LC3B2 recognizes:
| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| ATG7 | Thioester bond | E1 enzyme |
| ATG3 | Thioester bond | E2 enzyme |
| p62/SQSTM1 | LIR binding | Selective autophagy |
| OPTN | LIR binding | Selective autophagy |
| TRIM20 | LIR binding | Mitophagy receptor |
In AD:
In PD:
In HD:
In ALS:
| Approach | Agent | Status | Mechanism |
|----------|-------|--------|-----------|
| [mTOR](/entities/mtor) inhibitors | Rapamycin | Research | Autophagy induction |
| AMPK activators | Metformin | Research | Autophagy induction |
| [TFEB](/entities/tfeb) activators | Gene therapy | Experimental | Lysosomal biogenesis |
| Autophagy enhancers | Trehalose | Research | [mTOR](/mechanisms/mtor-signaling-pathway)-independent |
The study of Map1Lc3B2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.